A broader question might be to what extent are companies being forced by the unreasonable demands of this 'clunky' system to make this kind of proposal. Isn't the proposal a response to something? MSAC would be wise to consider what that something is rather than issue statements shifting blame and insulting healthcare companies. …
Where does the system end if statements like this become a feature of our decision-making?
July 8, 2024 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Cathy Freeman to headline 2026 Patient’s Choice Awards
August 27, 2026 - - Latest News -
Australian company secures Mitsubishi partnership to bring BioPQQ to market
August 26, 2026 - - Latest News -
Noxopharm pushes Sofra platform towards cancer proof of concept
August 26, 2026 - - Australian Biotech -
Argent BioPharma takes CannEpil into US veterinary regulatory process
August 26, 2026 - - Latest News -
Entropy takes TRP-8803 to the US in head-to-head depression trial
August 26, 2026 - -
Neuren’s first dividend signals a new phase built on DAYBUE royalties
August 26, 2026 - - Australian Biotech -
Starpharma narrows loss as Genentech deal lifts revenue and new funding extends runway
August 26, 2026 - - Australian Biotech